Sanofi, DiCE Molecules collaborate to replace injections with new oral medicines
Sanofi and DiCE Molecules have signed a research collaboration agreement to discover new drugs that may potentially replace injections to treat several diseases.
DiCE is a privately-held startup, which focuses on the development of next-generation methods to small molecule drug discovery.
The collaboration will see Sanofi pay an initial $50m to access DiCE's technology and take an equity stake in the company.
DiCE's technology platform selects and optimizes low molecular weight compounds against targets to address chemistry issues and allow monoclonal antibodies to be replaced by orally administered medicines.
Click on this link for more information.